Compare Abbott Laboratories (ABT) vs Nokia Corp (NOK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Nokia Corp — how do they compare? Abbott Laboratories trades at $95.62 (market cap $166.94B), while Nokia Corp trades at $11.76 (market cap $66.24B). The key difference: Abbott Laboratories is far larger — about 2.5× Nokia Corp's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | NOK | |
|---|---|---|
Market Cap | $166.94B | $66.24B |
Sector | Health | Technology |
52-Week High | $136.62 | $16.83 |
52-Week Low | $82.57 | $4.05 |
Enterprise Value | $193.69B | $63.06B |
Dividend Yield | 2.63% | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Nokia (NOK) trades at $11.85, down 1.74% amid a bearish technical signal, despite strong year-to-date performance. The company shows mixed fundamentals with a high P/E of 78.47 but recent earnings beats and a 44.12% gross margin. Recent news highlights Nokia's strategic pivot to AI infrastructure, including partnerships with Nvidia and Amazon Web Services, driving investor optimism about future growth potential in network modernization and data center markets.
Outlook remains cautiously optimistic with a consensus price target of $18.00 representing 52% upside, though high valuation and recent earnings miss pose risks. The stock's direction hinges on execution of AI initiatives and Q2 2026 earnings results due July 23, with technical indicators suggesting near-term consolidation near current support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
